Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Launches Ozempic Pills Across 70,000 US Pharmacies
10:40am, Friday, 01'st May 2026
Novo Nordisk (NVO) is making a more deliberate push into the US diabetes market by relaunching an existing, less-popular tablet under the Ozempic name, using on
Novo Nordisk rolls out Ozempic pill in the U.S.
10:39am, Friday, 01'st May 2026
Novo Nordisk (NVO) is giving one of its biggest drugs a new twist, rolling out an Ozempic pill in the U.S. starting next week.The company says the oral version
Fast Money Panel Says Novo Nordisk Now More Compelling Than Eli Lilly After Falling 70%
08:05pm, Thursday, 30'th Apr 2026
CNBC's Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO Price Prediction) now offers a more compelling setup than GLP-1 category leader
Eli Lilly, Novo Stocks Jump as FDA Moves to Limit Compounded GLP-1 Drugs
02:03pm, Thursday, 30'th Apr 2026
Eli Lilly (LLY) and Novo Nordisk (NVO) climbed Thursday after the U.S. Food and Drug Administration said it may tighten limits on pharmacies that make compounde
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
11:02am, Thursday, 30'th Apr 2026
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that ou
US FDA proposes excluding weight-loss drugs from compounding list
09:54am, Thursday, 30'th Apr 2026
The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs on the list of drugs outsourcing facilities can use
WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook
08:00am, Thursday, 30'th Apr 2026
PERTH, Australia, April 30, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO & NVOO) (TSX: NVO) (OTCQX: NSRPF) is pleased to invite shareholders and investors to a Webina
Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview)
07:45am, Thursday, 30'th Apr 2026
Novo Nordisk faces sustained margin compression due to intensifying price competition in the GLP-1 weight loss drug market. Gross profit margin has declined from over 84% to 80%, and profit margin fro
Meta is heading into earnings with a big move expected
02:11pm, Wednesday, 29'th Apr 2026
Novo Nordisk (NVO) just got an early reminder that competition is starting to creep in around its blockbuster drug Ozempic, at least in Canada.Health Canada has
Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
12:37pm, Wednesday, 29'th Apr 2026
The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.
Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth
08:27am, Wednesday, 29'th Apr 2026
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of money and added that he would rather have to find something new and different that is distinct, wh
Health Canada approves first generic version of Novo Nordisk's Ozempic
05:06pm, Tuesday, 28'th Apr 2026
Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made by Indian drugmaker Dr Reddy's Laborator
Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?
11:16am, Tuesday, 28'th Apr 2026
Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieve
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
02:03am, Tuesday, 28'th Apr 2026
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesit
